| payload |
{"created_at":"2026-04-10T19:36:12.043 {"created_at":"2026-04-10T19:36:12.043019+00:00","dedupe_key":"signal_enriched:news_delta:bb14296ea50abd71","evidence_event_ids":["evt_e62794f9e46a"],"signal_type":"news_headline_delta","source":"news_rss","value":{"aggregator_url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxQVFROX19Dd2N5T1ZCWGJ1X1RaVU9EUFJ6M3NTR055azZWWWFHYVNhbHltTDBSdkR0TUpMM05iVTM3YWJiOTNsNldVWGZLYjV0elBtZjhTYzB6b1VCN2xjeTVCRkQ3aFdXMDNmSTRkRGQxcjZFT0E0Vk9jX0RwSXNPd2dybkFoUk9iZUIxZFRFalpWa1N1OHltUThCUVd6Mmd2LVIzTm5KbEk0aENOa3VuZGNGVURZWXc4NUczSTV6WFhrV3MwTXRuaC02VVAtYVYwZmprUVlqcVpkdzRfbkdPdmRB?oc=5","as_of":"2026-04-10T19:36:12.043019+00:00","canonical_url":"https://www.gstatic.com/_/mss/boq-dots/_/ss/k=boq-dots.DotsSplashUi_desktop_ms.OYgPNdDf9Nc.L.X.O/am=GAIFAAAADpgFDCgAAQ/d=1/ed=1/rs=ALs0n2OYSmDAUDetpsORI83j3dpsv55GJQ/m=syndicationarticleview,_b,_tp","enrichment":{"aggregator_url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxQVFROX19Dd2N5T1ZCWGJ1X1RaVU9EUFJ6M3NTR055azZWWWFHYVNhbHltTDBSdkR0TUpMM05iVTM3YWJiOTNsNldVWGZLYjV0elBtZjhTYzB6b1VCN2xjeTVCRkQ3aFdXMDNmSTRkRGQxcjZFT0E0Vk9jX0RwSXNPd2dybkFoUk9iZUIxZFRFalpWa1N1OHltUThCUVd6Mmd2LVIzTm5KbEk0aENOa3VuZGNGVURZWXc4NUczSTV6WFhrV3MwTXRuaC02VVAtYVYwZmprUVlqcVpkdzRfbkdPdmRB?oc=5","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_0aff34e0762491e3","canonical_host":"gstatic.com","canonical_is_aggregator":true,"canonical_url":"https://www.gstatic.com/_/mss/boq-dots/_/ss/k=boq-dots.DotsSplashUi_desktop_ms.OYgPNdDf9Nc.L.X.O/am=GAIFAAAADpgFDCgAAQ/d=1/ed=1/rs=ALs0n2OYSmDAUDetpsORI83j3dpsv55GJQ/m=syndicationarticleview,_b,_tp","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-10T20:15:55.374237+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"","final_url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxQVFROX19Dd2N5T1ZCWGJ1X1RaVU9EUFJ6M3NTR055azZWWWFHYVNhbHltTDBSdkR0TUpMM05iVTM3YWJiOTNsNldVWGZLYjV0elBtZjhTYzB6b1VCN2xjeTVCRkQ3aFdXMDNmSTRkRGQxcjZFT0E0Vk9jX0RwSXNPd2dybkFoUk9iZUIxZFRFalpWa1N1OHltUThCUVd6Mmd2LVIzTm5KbEk0aENOa3VuZGNGVURZWXc4NUczSTV6WFhrV3MwTXRuaC02VVAtYVYwZmprUVlqcVpkdzRfbkdPdmRB?oc=5&hl=en-US&gl=US&ceid=US:en","html_truncated":true,"paywall_likely":false,"publisher_domain":"reuters.com","publisher_resolution":"payload_source_domain","requested_url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxQVFROX19Dd2N5T1ZCWGJ1X1RaVU9EUFJ6M3NTR055azZWWWFHYVNhbHltTDBSdkR0TUpMM05iVTM3YWJiOTNsNldVWGZLYjV0elBtZjhTYzB6b1VCN2xjeTVCRkQ3aFdXMDNmSTRkRGQxcjZFT0E0Vk9jX0RwSXNPd2dybkFoUk9iZUIxZFRFalpWa1N1OHltUThCUVd6Mmd2LVIzTm5KbEk0aENOa3VuZGNGVURZWXc4NUczSTV6WFhrV3MwTXRuaC02VVAtYVYwZmprUVlqcVpkdzRfbkdPdmRB?oc=5","source_event_id":"evt_e62794f9e46a","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"abf11b90225ebcb9","published_at":"2026-04-10T12:18:16+00:00","publisher_domain":"reuters.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.62,"dates_mentioned":[],"entities":[{"asset_class":"healthcare","name":"GLP-1 receptor agonist weight-loss drugs","relevance":"high","symbol":"","type":"drug_class"},{"asset_class":"healthcare","name":"GLP-1 drugs (weight-loss jabs)","relevance":"high","symbol":"","type":"drug"},{"asset_class":"unknown","name":"Scientists / researchers","relevance":"medium","symbol":"","type":"group"},{"asset_class":"media","name":"Nature Genetics","relevance":"medium","symbol":"","type":"publication"}],"event_type":"research","information_gaps":["The specific genetic variants/loci and effect sizes are not provided in the supplied text.","Which GLP-1 drugs (e.g., semaglutide, liraglutide, tirzepatide) are covered is not specified in the provided excerpt.","The specific side effects studied and their direction/magnitude are not detailed in the provided excerpt.","Near-term timing for clinical translation (e.g., whether tests are imminent) is not stated in the provided excerpt.","No direct market/stock impact or company names are included in the provided text."],"key_facts":["Reuters headline indicates genetic variations are linked to weight loss outcomes from GLP-1 drugs.","Reuters headline indicates genetic variations are also linked to side effects from GLP-1 drugs.","The Reuters source summary states the work is reported in Nature Genetics.","The Reuters source summary frames the genetics as potentially explaining why GLP-1 results vary between individuals."],"numeric_claims":[],"primary_claim":"Genetic variations are linked to differences in weight loss and side effects among patients taking GLP-1 receptor agonist drugs.","relevance_score":0.55,"sentiment":"neutral","source_quality":"high","summary":"Reuters reports that genetic variations may predict both the degree of weight loss and the likelihood of side effects in people treated with GLP-1 receptor agonist weight-loss drugs. The finding is positioned as a potential explanation for why treatment responses vary across individuals.","topics":["genetics","pharmacogenomics","GLP-1 receptor agonists","weight loss","side effects","personalized medicine"]},"source":"Reuters","source_domain":"reuters.com","source_url":"https://www.reuters.com","summary":"Genetic variations linked to weight loss, side effects from GLP-1 drugs Reuters Genetic predictors of GLP1 receptor agonist weight loss and side effects Nature Genetics may help explain why results from weight-loss jabs vary, say scientists The Guardian Genetics could explain why weight loss drugs work better for some WFLA If you aren\u2019t losing weight with GLP-1 drugs, this may be one reason why The Washington Post","title":"Genetic variations linked to weight loss, side effects from GLP-1 drugs - Reuters","url":"https://www.gstatic.com/_/mss/boq-dots/_/ss/k=boq-dots.DotsSplashUi_desktop_ms.OYgPNdDf9Nc.L.X.O/am=GAIFAAAADpgFDCgAAQ/d=1/ed=1/rs=ALs0n2OYSmDAUDetpsORI83j3dpsv55GJQ/m=syndicationarticleview,_b,_tp"}}... |